Background of Injectafer
Injectafer, also known as ferric carboxymaltose, is an intravenous iron supplement approved by the United States FDA (Food and Drug Administration) in 2013. This medicine belongs to a class known as iron replacement products.
Injectafer is often utilized by patients who cannot tolerate or respond well to oral iron supplements. Inside the drug is iron (III) hydroxide poly maltose in a carboxymaltose shell for slow release and longer-lasting benefits than most iron supplements.
Although Injectafer has proven highly successful at treating iron deficiency anemia, recent concerns about its safety and potential risks have surfaced. Some patients have reported severe allergic reactions, including anaphylaxis.
Before beginning treatment with Injectafer, it is vital that you discuss both its potential risks and benefits with your healthcare provider. Healthcare providers should closely monitor patients for possible adverse side effects during and after post-therapy.
If you experience severe complications or adverse reactions after using Injectafer, legal assistance may be necessary in order to hold the manufacturer responsible. Consulting an experienced attorney may help individuals understand their legal rights and options better.